Printer Friendly

Mylan unveils first US FDA approved generic Klor-Con Extended-Release Tablets.

M2 EQUITYBITES-August 25, 2014-Mylan unveils first US FDA approved generic Klor-Con Extended-Release Tablets

(C)2014 M2 COMMUNICATIONS http://www.m2.com

Pharmaceutical company Mylan (NasdaqGS:MYL) reported on Friday the availability of Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg) in the market.

The company said that the US Food and Drug Administration (FDA) approved Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg) as a generic version of Upsher-Smith's Klor-Con.

Potassium Chloride Extended-release Tablets USP are indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. Mylan has begun shipping this product, according to the company.

For the 12 months ending 30 June 2014, Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), had US sales of USD135.05m, according to IMS Health.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 25, 2014
Words:165
Previous Article:DISH announces retirement of CFO; Steve Swain to serve as new CFO.
Next Article:Dannemora Mineral reduces loss in period 1 January to 30 June 2014.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters